Literature DB >> 8208903

Outcome of treatment in young adults with phenylketonuria detected by routine neonatal screening between 1964 and 1971.

M G Beasley1, P M Costello, I Smith.   

Abstract

Intellectual status at 18 years is reported in 192 patients with phenylketonuria born in the UK between 1964 and 1971, together with their school progress. Mean IQs expressed as standard deviation scores (IQ-SDS) were significantly below estimated population norms, and showed a small decrease from 14 to 18 years of age (mean IQ-SDS -1.06 +/- 1.3 at 14 years and -1.28 +/- 1.07 at 18 years, t = 5.7, p < 0.0001). At 18 years, 27% of subjects had IQs over 2 SDs below the estimated population mean. IQ-SDS at 18 years, although significantly related to average phenylalanine control both between birth and 14 years, and between 14 and 18 years, was not independently related to either variable after allowing for IQ-SDS at 14 years. We conclude that general ability in young adults with early treated phenylketonuria, although reduced in comparison with their peers and closely related to phenylalanine control in early childhood, is not directly influenced by phenylalanine control in the four years preceding the 18th birthday. The apparent fall in IQ-SDS between 14 and 18 years may be due to methodological problems in the analysis of longitudinal IQ data without a control group, rather than providing evidence of intellectual decline.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8208903

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  12 in total

1.  Newborn and childhood screening programmes: criteria, evidence, and current policy.

Authors:  D A C Elliman; C Dezateux; H E Bedford
Journal:  Arch Dis Child       Date:  2002-07       Impact factor: 3.791

2.  Wechsler subscale IQ and subtest profile in early treated phenylketonuria.

Authors:  P V Griffiths; C Demellweek; N Fay; P H Robinson; D C Davidson
Journal:  Arch Dis Child       Date:  2000-03       Impact factor: 3.791

3.  Effect of genotype on changes in intelligence quotient after dietary relaxation in phenylketonuria and hyperphenylalaninaemia.

Authors:  L G Greeves; C C Patterson; D J Carson; R Thom; M C Wolfenden; J Zschocke; C A Graham; N C Nevin; E R Trimble
Journal:  Arch Dis Child       Date:  2000-03       Impact factor: 3.791

4.  Effects of dietary management of phenylketonuria on long-term cognitive outcome.

Authors:  Shelley Channon; Galya Goodman; Sally Zlotowitz; Caroline Mockler; Philip J Lee
Journal:  Arch Dis Child       Date:  2006-10-26       Impact factor: 3.791

5.  Intelligence patterns among children with high-functioning autism, phenylketonuria, and childhood head injury.

Authors:  M Dennis; L Lockyer; A L Lazenby; R E Donnelly; M Wilkinson; W Schoonheyt
Journal:  J Autism Dev Disord       Date:  1999-02

6.  Predictability and inconsistencies in the cognitive outcome of early treated PKU patients.

Authors:  Filippo Manti; Francesca Nardecchia; Sabrina Paci; Flavia Chiarotti; Claudia Carducci; Carla Carducci; Silvia Dalmazzone; Graziella Cefalo; Elisabetta Salvatici; Giuseppe Banderali; Vincenzo Leuzzi
Journal:  J Inherit Metab Dis       Date:  2017-08-23       Impact factor: 4.982

Review 7.  Use of registers in child health.

Authors:  A Johnson
Journal:  Arch Dis Child       Date:  1995-06       Impact factor: 3.791

8.  Developmental timing of exposure to elevated levels of phenylalanine is associated with ADHD symptom expression.

Authors:  Kevin M Antshel; Susan E Waisbren
Journal:  J Abnorm Child Psychol       Date:  2003-12

9.  Intelligence and professional career in young adults treated early for phenylketonuria.

Authors:  H Schmidt; P Burgard; J Pietz; A Rupp
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

10.  Phenylketonuria: treatment in adolescence and adult life.

Authors:  D P Brenton; A C Tarn; J C Cabrera-Abreu; M Lilburn
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.